A Phase 1 multicenter, open label study of enadenotucirev combined with PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
PsiOxus Therapeutics Ltd.
Start Date
July 27, 2018
End Date
April 16, 2020
Administered By
Duke Cancer Institute
Awarded By
PsiOxus Therapeutics Ltd.
Start Date
July 27, 2018
End Date
April 16, 2020